Should new health technology be available only for patients able and willing to pay? [0.03%]
新的医疗技术应该只为那些愿意并且能够支付的病人提供吗？
Piet Calcoen,Albert Boer,Wynand P M M van de Ven
Piet Calcoen
New health technology comes on the market at a rapid pace and - sometimes - at a huge cost. Providing access to new health technology is a serious challenge for many countries with mandatory health insurance. This article analyses access to...
John J O Mogaka,Lucia Mupara,Joyce M Tsoka-Gwegweni
John J O Mogaka
Global disparities in medical technologies, laws, economic inequities, and social-cultural differences drive medical tourism (MT), the practice of travelling to consume healthcare that is either too delayed, unavailable, unaffordable or leg...
Supply-side and demand-side policies for biosimilars: an overview in 10 European member states [0.03%]
欧洲10个成员国的生物类似药供给方和需求方政策综述
Cécile Rémuzat,Anna Kapuśniak,Aleksandra Caban et al.
Cécile Rémuzat et al.
This study aimed to provide an overview of biosimilar policies in 10 EU MSs. Methods: Ten EU MS pharmaceutical markets (Belgium, France, Germany, Greece, Hungary, Italy, Poland, Spain, Sweden, and the UK) were selected. A comprehensive lite...
Unlocking the potential of established products: toward new incentives rewarding innovation in Europe [0.03%]
激发老产品的潜在价值：在欧洲建立激励创新的新机制
Gabrielle Nayroles,Sandrine Frybourg,Sylvie Gabriel et al.
Gabrielle Nayroles et al.
Background: Many established products (EPs - marketed for eight years or more) are widely used off-label despite little evidence on benefit-risk ratio. This exposes patients to risks related to safety and lack of efficacy, and healthcare pr...
Filling the gap in CNS drug development: evaluation of the role of drug repurposing [0.03%]
填补中枢神经系统药物研发空白：评估药物再定位的作用
A Caban,K Pisarczyk,K Kopacz et al.
A Caban et al.
Background and objective: Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs. Little is known and documented regarding the efficiency of repurposing strategies ...
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe [0.03%]
罕见病药物的欧洲市场定价策略研究
Goran Medic,Daria Korchagina,Katherine Eve Young et al.
Goran Medic et al.
Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed t...
Katherine Eve Young,Imen Soussi,Michiel Hemels et al.
Katherine Eve Young et al.
Background and Objective: This study assessed price differences by comparing annual treatment costs of similarly available orphan drugs in France, Germany, Italy, Norway, Spain, Sweden, and UK. Methods: Annual treatment costs per drug were ...
Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiative [0.03%]
前瞻性注册登记数据在创新型医疗器械临床试验设计中的作用——健康政策倡议中的一小步但不可或缺的一步
Donald R Ricci,Joost de Vries,Raphael Blanc
Donald R Ricci
Establishing a national health policy at a macro level involves the integration of a series of health initiatives across a spectrum of activities, including clinical care. Evaluation of the safety and efficacy of a new medical device ultima...
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy [0.03%]
贝达喹啉在意大利耐多药和耐极端多药结核病中的成本效益分析
Luigi R Codecasa,Mondher Toumi,Anna D&#x;Ausilio et al.
Luigi R Codecasa et al.
Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted...
Cécile Rémuzat,Julie Dorey,Olivier Cristeau et al.
Cécile Rémuzat et al.
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all av...